Arti K. Rai, J.D.
doi : 10.1056/NEJMp2202098
Vol. 388 No. 17
Neal L. Benowitz, M.D., Kenneth E. Warner, Ph.D., Matthew L. Myers, J.D., Dorothy Hatsukami, Ph.D., Micah L. Berman, J.D., Donna Vallone, Ph.D., and Joanna E. Cohen, Ph.D.
doi : 10.1056/NEJMp2301700
Leanna Lewis, M.S.W., Camila Cribb Fabersunne, M.D., M.P.H., Corina L. Iacopetti, M.D., Gabby Negussie-Retta, M.S., Dannielle McBride, M.D., Paul Irving, B.A., and Jyothi Marbin, M.D.
doi : 10.1056/NEJMp2212866
Freddie C. Hamdy, F.R.C.S.(Urol.), F.Med.Sci., Jenny L. Donovan, Ph.D., F.Med.Sci., J. Athene Lane, Ph.D., Chris Metcalfe, Ph.D., Michael Davis, M.Sc., Emma L. Turner, Ph.D., Richard M. Martin, B.M., B.S., Ph.D., Grace J. Young, M.Sc., Eleanor I. Walsh, M.Sc., Richard J. Bryant, Ph.D., F.R.C.S.(Urol.), Prasad Bollina, M.B., B.S., F.R.C.S.(Urol.), Andrew Doble, F.R.C.S.(Urol.),
doi : 10.1056/NEJMoa2214122
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed in 2664 men. Of these men, 1643 were enrolled in a trial to evaluate the effectiveness of treatments, with 545 randomly assigned to receive active monitoring, 553 to undergo prostatectomy, and 545 to undergo radiotherapy.
Caroline F. Wright, Ph.D., Patrick Campbell, M.B., B.S., Ruth Y. Eberhardt, Ph.D., Stuart Aitken, Ph.D., Daniel Perrett, M.Phil., Simon Brent, B.Sc., Petr Danecek, Ph.D., Eugene J. Gardner, Ph.D., V. Kartik Chundru, Ph.D., Sarah J. Lindsay, Ph.D., Katrina Andrews, M.B., B.Ch., Juliet Hampstead, B.Sc.,
doi : 10.1056/NEJMoa2209046
Pediatric disorders include a range of highly penetrant, genetically heterogeneous conditions amenable to genomewide diagnostic approaches. Finding a molecular diagnosis is challenging but can have profound lifelong benefits.
Inge M. van der Sluis, M.D., Ph.D., Paola de Lorenzo, Ph.D., Rishi S. Kotecha, M.B., Ch.B., Ph.D., Andishe Attarbaschi, M.D., Gabriele Escherich, M.D., Karsten Nysom, M.D., Ph.D., Jan Stary, M.D., Ph.D., Alina Ferster, M.D., Benoit Brethon, M.D., Franco Locatelli, M.D., Ph.D., Martin Schrappe, M.D., Peggy E. Scholte-van Houtem, M.Sc., Maria G. Valsecchi, Ph.D., and Rob Pieters, M.D., Ph.D.
doi : 10.1056/NEJMoa2214171
KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.
Laure F. Pittet, Ph.D., Nicole L. Messina, Ph.D., Francesca Orsini, M.Sc., Cecilia L. Moore, Ph.D., Veronica Abruzzo, M.Clin.Epi., Simone Barry, Ph.D., Rhian Bonnici, B.Sc., Marc Bonten, Ph.D., John Campbell, M.D., Julio Croda, Ph.D., Margareth Dalcolmo, Ph.D., Kaya Gardiner, M.P.H.,
doi : 10.1056/NEJMoa2212616
The bacille Calmette–Guérin (BCG) vaccine has immunomodulatory “off-target� effects that have been hypothesized to protect against coronavirus disease 2019 (Covid-19).
John S. Brownstein, Ph.D., Benjamin Rader, M.P.H., Christina M. Astley, M.D., Sc.D., and Huaiyu Tian, Ph.D.
doi : 10.1056/NEJMra2119215
Salim N. Najjar, M.D., and Alec B. Rezigh, M.D.
doi : 10.1056/NEJMicm2211456
Ting-Han Tai, M.D., and Chih-Yu Chen, M.D., Ph.D.
doi : 10.1056/NEJMicm2211242
Leigh H. Simmons, M.D., Mladen Nisavic, M.D., and Amy K. Dickey, M.D.
doi : 10.1056/NEJMcpc2300896
Jennifer E. Posey, M.D., Ph.D., and James R. Lupski, M.D., Ph.D.
doi : 10.1056/NEJMe2302643
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Quarraisha Abdool Karim, Ph.D., Salim S. Abdool Karim, M.B., Ch.B., Ph.D., Richard P. Wenzel, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2305010
Leslie L. Chang, M.D., Jacqueline T. DesJardin, M.D., Michelle A. Albert, M.D., M.P.H., Justin Ezekowitz, M.B., B.Ch., and Salim Yusuf, M.D., D.Phil.
doi : 10.1056/NEJMclde2215283
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟